Join this Endpoints at BIO International virtual event where R&D execs from Amgen, GSK, Janssen, Takeda, and Catalent discuss how they’ve reorganized global teams, tapped new programs as a priority to fight COVID-19, and what they plan for the future after the pandemic.
David Reese：Executive VP, Research & Development, Amgen
Hal Barron：CSO & President, R&D, GlaxoSmithKline
Mathai Mammen：Global Head of R&D, Janssen、Pharma Company of J&J
Andrew Plump：President, Research & Development, Takeda
John Chiminski：Chair & CEO, Catalent